Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | GeneDx Holdings Corp.: GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset | 61 | GlobeNewswire (Europe) | STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo... ► Artikel lesen | |
04.04. | GeneDx Holdings Corp.: GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 | 2 | GlobeNewswire (USA) | ||
14.03. | GeneDx Holdings Corp.: GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics | 1 | GlobeNewswire (USA) | ||
26.02. | GeneDx Holdings Corp.: GeneDx to Participate in 44th Annual Cowen Health Care Conference | 1 | GlobeNewswire (USA) | ||
23.02. | GeneDx Holdings Corp. - 10-K, Annual Report | - | SEC Filings | ||
21.02. | Earnings call: GeneDx posts revenue rise, eyes profitability by 2025 | 1 | Investing.com | ||
20.02. | GeneDx reports Q4 results | 1 | Seeking Alpha | ||
20.02. | GeneDx Holdings Corp.: GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 | 222 | GlobeNewswire (Europe) | Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins2... ► Artikel lesen | |
20.02. | GeneDx Holdings Corp. - 8-K, Current Report | - | SEC Filings | ||
19.02. | Earnings Preview: GeneDx Holdings | 1 | Benzinga.com | ||
01.02. | GeneDx Holdings Corp.: GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 | 2 | GlobeNewswire (USA) | ||
30.01. | Sema4.ai Raises $30.5M in Funding | 1 | FinSMEs | ||
30.01. | Sema4.ai: $30.5 Million Secured To Build Intelligent Agents For Helping Knowledge Workers | 1 | pulse2.com | ||
29.01. | AI startup Sema4.ai, led by former Cloudera CEO Rob Bearden, raises $30.5M | 1 | SiliconANGLE | ||
29.01. | Sema4.ai Secures $30.5 Million to Bring AI to Enterprise Work | 1 | PYMNTS.com | ||
24.01. | GeneDx Holdings Corp.: GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
08.01. | GeneDx Holdings stock soars after company forecasts upbeat Q4 guidance, reiterates profitability outlook | 1 | Seeking Alpha | ||
08.01. | GeneDx Holdings Corp.: GeneDx Announces Preliminary 2023 Financial Results | 221 | GlobeNewswire (Europe) | Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome... ► Artikel lesen | |
08.01. | GeneDx Holdings Corp. - 8-K, Current Report | - | SEC Filings | ||
01.12.23 | GeneDx Holdings Corp.: GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy | 373 | GlobeNewswire (Europe) | STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be presented... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ECKERT & ZIEGLER | 36,720 | +1,89 % | Eckert & Ziegler gutes Q1 - reicht zumindest für Prognosebestätigung. Und Kursfeuerwerk. Eintagsfliege? | Eckert & Ziegler (ISIN: DE0005659700) - Anfang Januar noch beim Platow Brief als klarer KAUF eingestuft - liefert heute im Rahmen einer ad-hoc-Meldung einen vorläufigen Blick auf die Q1-Zahlen, die... ► Artikel lesen | |
INTUITIVE SURGICAL | 351,90 | +0,34 % | Intuitive Surgical-Aktie: 5 Gründe für den Kauf | Seit ihrem Allzeithoch Ende März hat die Intuitive Surgical-Aktie (WKN: 888024) rund -8% an Wert abgegeben. Werden die Quartalszahlen dem Hersteller von Operationsrobotern neuen Schwung verleihen? Intuitive... ► Artikel lesen | |
ROKU | 52,72 | +0,13 % | Roku: Wachstum beschleunigt sich, Verluste weiter reduziert | SAN JOSE, Kalifornien (IT-Times) - Roku, Anbieter von Hard- und Software für Video-Streaming-Services, hat seine Ergebnisse für das Auftaktquartal 2024 veröffentlicht und ein zweistelliges Wachstum... ► Artikel lesen | |
BICO GROUP | 3,882 | -0,46 % | Bico Group Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
ATOSSA THERAPEUTICS | 1,504 | +5,47 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen | SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen | |
ASENSUS SURGICAL | 0,238 | +1,71 % | Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG | RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) ("Asensus" or the "Company"), a medical device company that is digitizing the interface... ► Artikel lesen | |
QUIDELORTHO | 37,000 | -0,54 % | QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care... ► Artikel lesen | |
VERU | 1,164 | -1,52 % | Veru Inc.: Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 | ||
TEMPEST THERAPEUTICS | 3,370 | +2,12 % | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
CENTENE | 68,28 | -1,27 % | Centene-Aktie legt um 0,84 Prozent zu (71,0929 €) | Im Plus liegt aktuell das Wertpapier von Centene . Das Papier kostete zuletzt 75,78 US-Dollar. Heute hat sich an der US-amerikanischen Börse die Centene-Aktie zwischenzeitlich um 0,84 Prozent verteuert.... ► Artikel lesen | |
BONESUPPORT | 19,200 | -0,57 % | Bonesupport Holding AB publishes Q1 2024 Interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2024.
THE GROWTH JOURNEY CONTINUESJANUARY... ► Artikel lesen | |
PERSPECTIVE THERAPEUTICS | 1,520 | +2,01 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results | SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout... ► Artikel lesen | |
LANTHEUS | 61,00 | -0,49 % | Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings | ||
OMNICELL | 25,400 | -3,05 % | Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today... ► Artikel lesen |